What Is Addyi and How Does It Work
Addyi (flibanserin) is a prescription medication for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). The little pink pill was first approved by the U.S. Food and Drug Administration on August 18, 2015. It acts on brain neurotransmitters, specifically serotonin and dopamine, to increase sexual desire. The drug is manufactured by Sprout Pharmaceuticals and is taken once daily at bedtime. Addyi is not a hormone and is not intended for use after menopause.
The FDA originally granted Addyi priority review and a priority voucher, but the approval came with a Risk Evaluation and Mitigation Strategy (REMS). The REMS program requires certified healthcare providers and pharmacies to dispense the drug. This program was designed to manage the risk of severe low blood pressure and fainting, especially when combined with alcohol. The REMS status remains active as of the latest public FDA records.
Addyi Sales, Pricing, and Market Position
Addyi generated approximately $1.2 billion in U.S. net sales in 2023, according to Sprout Pharmaceuticals' public reporting. The drug is priced at roughly $100 for a 30-day supply without insurance, though manufacturer coupons and patient assistance programs can reduce out-of-pocket costs. Addyi competes in the sexual health space alongside Viagra and Cialis, but it targets a different patient population and mechanism. It remains one of the few FDA-approved treatments specifically for low sexual desire in women.
Market analysts have tracked Addyi's revenue growth as a niche women's health product. The company has focused on direct-to-consumer advertising and provider education to expand prescriptions. Addyi's commercial performance has been closely watched by investors as a bellwether for the women's sexual health market. The drug's branded marketing emphasizes its role in addressing a specific diagnosed condition rather than general libido enhancement.
Regulatory History, Safety Data, and Current Status
The FDA initially declined to approve Addyi in 2010 and again in 2013 before granting approval in 2015. The decision was controversial, with advisory committee votes split along gender lines. The FDA's approval was based on clinical trials showing a statistically significant increase in sexually satisfying events compared to placebo. The most common side effects include dizziness, sleepiness, nausea, and fatigue. The label carries a boxed warning against alcohol use due to the risk of syncope.
Sprout Pharmaceuticals later launched a direct-to-consumer advertising campaign that became one of the most recognized in pharmaceutical marketing. The company's promotional practices have been reviewed by industry sources and regulatory watchers. Addyi remains on the market with the same REMS requirements, and no new major FDA safety actions have been reported recently. The latest public data continues to position Addyi as a unique, FDA-approved option for premenopausal women with HSDD. For more details on the FDA approval and REMS program, see the official FDA page on Addyi here.